These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32427166)

  • 1. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.
    Daughton CG
    Glob Epidemiol; 2020 Nov; 2():100026. PubMed ID: 32427166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Deeks JJ; Adriano A; Berhane S; Davenport C; Dittrich S; Emperador D; Takwoingi Y; Cunningham J; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Taylor-Phillips S; Hooft L; Leeflang MM; Spijker R; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013705. PubMed ID: 32845525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Sharma P; Berhane S; van Wyk SS; Nyaaba N; Domen J; Taylor M; Cunningham J; Davenport C; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Van den Bruel A; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013705. PubMed ID: 35866452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronavirus Disease -2019 (COVID-19) in 2020: A Perspective Study of a Global Pandemic.
    Bhat MA; Rahman S; Rather IA; Banday MI; Syed S; Koser H; Kamal MA; Minakshi R; Jan AT
    Curr Pharm Des; 2021; 27(32):3435-3443. PubMed ID: 33213324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better the drug you know: Commentary on "Daughton 2020, Natural experiment concept to accelerate the re-purposing of existing therapeutics for Covid-19".
    Broadbent A
    Glob Epidemiol; 2020 Nov; 2():100027. PubMed ID: 32427188
    [No Abstract]   [Full Text] [Related]  

  • 13. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to: Broadbent 2020, Better the drug you know: Commentary on "Daughton 2020, Natural experiment concept to accelerate the re-purposing of existing therapeutics for Covid-19".
    Daughton CG
    Glob Epidemiol; 2020 Nov; 2():100028. PubMed ID: 32501449
    [No Abstract]   [Full Text] [Related]  

  • 15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
    Huang F; Li Y; Leung EL; Liu X; Liu K; Wang Q; Lan Y; Li X; Yu H; Cui L; Luo H; Luo L
    Pharmacol Res; 2020 Aug; 158():104929. PubMed ID: 32442720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
    Toor HG; Banerjee DI; Lipsa Rath S; Darji SA
    Eur J Pharmacol; 2021 Jan; 890():173720. PubMed ID: 33160938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2.
    Gupta AK; Khan MS; Choudhury S; Mukhopadhyay A; Sakshi ; Rastogi A; Thakur A; Kumari P; Kaur M; Shalu ; Saini C; Sapehia V; Barkha ; Patel PK; Bhamare KT; Kumar M
    Front Microbiol; 2020; 11():1858. PubMed ID: 32849449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus.
    Omolo CA; Soni N; Fasiku VO; Mackraj I; Govender T
    Eur J Pharmacol; 2020 Sep; 883():173348. PubMed ID: 32634438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.